645391-89-5

Basic information

• Product Name: CarbaMic acid, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, phenylMethyl ester
• Synonyms: CarbaMic acid, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, phenylMethyl ester;(S)-benzyl (1-(4-hydroxyphenyl)ethyl)carbamate;MOFFBMMMWZMROW-LBPRGKRZSA-N
• CAS NO: 645391-89-5
• Molecular Formula: C₁₆H₁₇NO₃
• Molecular Weight: 271.31108
• Mol File: 645391-89-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CarbaMic acid, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, phenylMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, phenylMethyl ester(645391-89-5)
• EPA Substance Registry System: CarbaMic acid, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, phenylMethyl ester(645391-89-5)

Safety Data

• Hazardous Substances Data: 645391-89-5(Hazardous Substances Data)

Upstream product

• 1001094-89-8 (S)-4-(1-amino-ethyl)-phenol hydrobromid 
• 501-53-1 benzyl chloroformate 
• 221670-72-0 (S)-4-(1-amino-ethyl)-phenol 
• 6298-96-0 (S)-1-(4-methoxyphenyl)ethylamine 

Downstream Products

• 645391-91-9 (S)-benzyl 1-(4-(tert-butyldimethylsilyloxy)phenyl) ethylcarbamate 
• 1443670-38-9 C₂₄H₃₀N₂O₅ 
• 1620690-56-3 (R)-tert-butyl 3-(4-((S)-1-(benzyloxycarbonylamino)ethyl)phenoxy)pyrrolidine-1-carboxylate 

Relevant articles and documents

7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS

Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.

Pyrrolidine derivatives, pharmaceutical compositions and uses thereof

The invention relates to new pyrrolidine derivatives of the formula to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new pyrrolidine derivatives of the formula (I), wherein R1 to R3, Ar, L T and n are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceu